IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by MidWestOne Financial Group Inc.

MidWestOne Financial Group Inc. increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 42.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,805 shares of the medical research company’s stock after acquiring an additional 2,019 shares during the period. MidWestOne Financial Group Inc.’s holdings in IQVIA were worth $1,337,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its holdings in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Merit Financial Group LLC grew its holdings in shares of IQVIA by 32.8% during the 4th quarter. Merit Financial Group LLC now owns 4,293 shares of the medical research company’s stock worth $844,000 after purchasing an additional 1,060 shares during the period. UMB Bank n.a. increased its position in IQVIA by 72.8% during the 4th quarter. UMB Bank n.a. now owns 401 shares of the medical research company’s stock worth $79,000 after purchasing an additional 169 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in IQVIA by 16.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,172 shares of the medical research company’s stock valued at $230,000 after buying an additional 169 shares during the period. Finally, Harbor Investment Advisory LLC lifted its position in IQVIA by 4.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company’s stock valued at $253,000 after buying an additional 58 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of IQV opened at $144.90 on Wednesday. IQVIA Holdings Inc. has a 52 week low of $135.97 and a 52 week high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $25.07 billion, a price-to-earnings ratio of 19.32, a PEG ratio of 1.99 and a beta of 1.34. The stock has a 50 day moving average of $158.26 and a 200-day moving average of $184.98.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the previous year, the company posted $2.54 earnings per share. The firm’s revenue was up 2.5% on a year-over-year basis. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

IQV has been the subject of several recent research reports. Citigroup dropped their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Barclays lowered their price target on IQVIA from $170.00 to $165.00 and set an “equal weight” rating for the company in a report on Wednesday, May 7th. HSBC cut IQVIA from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. UBS Group lowered their target price on IQVIA from $255.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Finally, Morgan Stanley boosted their price target on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $228.14.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.